AbbVie 2012 Annual Report Download - page 38

ITEM 2. PROPERTIES
AbbVie’s corporate offices are located at 1 North Waukegan Road, North Chicago,
Illinois 60064-6400. AbbVie’s principal manufacturing plants are in the following locations:
United States Outside the United States
Abbott Park, Illinois* Campoverde di Aprilia, Italy
Barceloneta, Puerto Rico Cork, Ireland
Jayuya, Puerto Rico Ludwigshafen, Germany
North Chicago, Illinois Sligo, Ireland
Worcester, Massachusetts
* Leased property.
In addition to the above, AbbVie has other manufacturing facilities in the United States and
worldwide. AbbVie believes its facilities are suitable and provide adequate production capacity.
In the United States, including Puerto Rico, AbbVie owns one distribution center. AbbVie also has
four United States research and development facilities located at: Abbott Park, Illinois; North Chicago,
Illinois; Redwood City, California; and Worcester, Massachusetts. Outside the United States, AbbVie’s
principal research and development facilities are located in Shanghai, China and Ludwigshafen,
Germany.
Except as noted, the principal plants in the United States listed above are owned by AbbVie or
subsidiaries of AbbVie. The remaining manufacturing plants and all other facilities are owned or leased
by AbbVie or subsidiaries of AbbVie.
ITEM 3. LEGAL PROCEEDINGS
Subject to certain exceptions specified in the separation agreement, AbbVie assumed the liability
for, and control of, all pending and threatened legal matters related to its business, including liabilities
for any claims or legal proceedings related to products that had been part of its business but were
discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify
Abbott for any liability arising out of or resulting from such assumed legal matters. As of January 31,
2013 (except as noted below), AbbVie is involved in various claims, legal proceedings, and
investigations, including those described below. While it is not feasible to predict the outcome of such
pending claims, proceedings and investigations with certainty, management is of the opinion that their
ultimate resolution should not have a material adverse effect on AbbVie’s financial position, cash flows,
or results of operations.
Several cases are pending against AbbVie that generally allege Abbott and numerous other
pharmaceutical companies reported false pricing information in connection with certain drugs that are
reimbursable under Medicare and Medicaid. These cases brought by state Attorneys General generally
seek monetary damages and/or injunctive relief and attorneys’ fees. The following cases are pending in
state courts: Commonwealth of Kentucky, filed in September 2003 in the Circuit Court of Franklin
County, Kentucky; State of Wisconsin, filed in June 2004 in the Circuit Court of Dane County,
Wisconsin; State of Illinois, filed in February 2005 in the Circuit Court of Cook County, Illinois; and
State of Louisiana, filed in October 2010 in the Nineteenth Judicial District, Parish of Baton Rouge,
Louisiana. All other previously reported cases that were pending against AbbVie in state courts have
been settled. As previously reported, certain federal court cases were consolidated for pre-trial
purposes in the United States District Court for the District of Massachusetts under the Multi District
Litigation Rules as In re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL 1456. In the
fourth quarter of 2012, the only remaining MDL 1456 case, which was filed in August 2006 on behalf
of the State of South Carolina, was settled and dismissed with prejudice.
32